To help drug developers improve the robustness of their assays, SPT Labtech and Synthace have formed a strategic collaboration that allows them to combine Design of Experiments (DoE) capabilities with automated liquid handling. The partners say that the combined technologies will help companies accelerate their drug discovery and development timelines, improve experimental outcomes, and optimize their resources.
“By bringing together the power of automated liquid handling and advanced digital experiment design, our partnership with Synthace exemplifies how these technologies are truly better together,” said Joby Jenkins, SPT Labtech’s CTO. “This collaboration underscores our commitment to providing the life sciences community with the integrated tools they need to optimize workflows and unlock vital new breakthroughs.”
DoE is a technique that helps scientists assess the impact of multiple factors on their assays at the same time. The Synthace platform translates DoE designs into precise automation instructions for optimizing drug assays. Combining the capability with SPT Labtech’s dragonfly® discovery automated reagent dispenser will enable drug developers to set up complex plate-based assays rapidly and precisely.
“Ever since we first integrated the dragonfly with Synthace, we’ve been blown away by the science that these two technologies have enabled,” said Markus Gershater, co-founder and CSO at Synthace. “Together, they’ve helped make immensely powerful experiments possible, delivering clear results, even in the face of huge biological complexity.”
Recently, SPT Labtech announced a partnership with Olink to combine the Olink Explore® platform with firefly, SPT Labtech’s automated liquid handling platform. Earlier this year, the company also announced a co-marketing collaboration with Roche to deliver a streamlined method for Illumina-compatible next-generation sequencing library preparation that leveraged the firefly instrument.
